Charged nutritive proteins and methods
View Patent ↗Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.
1. A method of maintaining or increasing muscle mass and/or muscle strength in a mammalian subject, the method comprising providing to the mammalian subject a sufficient amount of a nutritive composition comprising a nutritive protein comprising a first polypeptide sequence, wherein the nutritive protein comprises the following properties: an aqueous solubility of at least 50 g/L at pH 7, a simulated gastric digestion half-life of less than 10 minutes, and wherein the first polypeptide sequence comprises a ratio of Leu residues to total amino acid residues of at least 6%, a ratio of essential amino acid residues to total amino acid residues of at least 34%, a ratio of branch chain amino acid residues to total amino acid residues of at least 18%, and 0, 1, 2, or 3 cysteine residues.
2. The method of claim 1 , wherein the subject is an elderly human subject at least 50 years old.
3. The method of claim 1 , wherein the subject suffers from or is at risk of developing age-related sarcopenia or cachexia.
4. The method of claim 1 , wherein the nutritive protein is produced by a recombinant microorganism.
5. The method of claim 1 , wherein the nutritive protein is a recombinant protein.
6. The method of claim 1 , wherein the nutritive protein is at least 50 amino acids long.
7. The method of claim 1 , wherein the nutritive protein further comprises a polypeptide tag for affinity purification.
8. The method of claim 1 , wherein the first polypeptide sequence comprises a ratio of branch chain amino acid residues to total amino acid residues of at least 20%; a ratio of Leu residues to total amino acid residues of at least 11%; and a ratio of essential amino acid residues to total amino acid residues of at least 44%.
9. The method of claim 1 , wherein the first polypeptide sequence comprises a ratio of branch chain amino acid residues to total amino acid residues of at least 23%; a ratio of Leu residues to total amino acid residues of at least 11%; and a ratio of essential amino acid residues to total amino acid residues of at least 44%.
10. The method of claim 1 , wherein the nutritive protein has a simulated gastric digestion half-life of less than 2 minutes.
11. The method of claim 1 , wherein the first polypeptide sequence has less than 50% global homology to a known toxin, and/or wherein the first polypeptide sequence has less than 50% global homology to a known allergen.
12. The method of claim 1 , wherein the nutritive protein, when present at a concentration of 50 g/L, does not form insoluble precipitates or aggregates in aqueous solution at 95° C. at pH7.
13. The method of claim 1 , wherein the nutritive protein is at least 90% pure relative to total protein and is formulated for oral administration as a liquid solution, slurry, suspension, gel, paste, powder, or solid.
14. The method of claim 1 , wherein a muscle fractional synthetic rate of a skeletal muscle in the mammalian subject is increased after the nutritive protein is provided.
15. The method of claim 1 , wherein the nutritive protein comprises a ratio of non-glycosylated to total amino acid residues of at least 90%.
16. The method of claim 1 , wherein the nutritive protein does not comprise N-linked glycosylation, O-linked glycosylation or both N-linked and O-linked glycosylation.
17. The method of claim 1 , wherein the nutritive protein is provided in a sufficient amount to induce a satiation response in the subject.
18. The method of claim 1 , wherein the nutritive protein is provided in a sufficient amount to induce a satiety response in the subject.
19. The method of claim 1 , wherein the nutritive protein is provided in a sufficient amount to increase thermogenesis.